Table 2

Gastrointestinal peptides in the control and irritable bowel syndrome (IBS) groups

Control subjects IBS
Saline Lipid Saline Lipid
CCK<0.4  (<0.4–0.7)>12.52-160(4.7–>12.5)0.7  (<0.4–9.6) 11.42-150 (2.7–>12.5)
Motilin65 (50–76) 73 (61–78)79 (63–131) 79 (63–122)
PP22 (15–35) 572-160 (24–74)23 (15–33) 372-150(23–71)
PYY20 (19–23) 302-160 (28–34)23 (16–25) 302-160 (27–36)
VIP8.0 (7.0–11.2) 11.02-160(8.8–13.8)7.0 (5.0–9.8) 11.02-150 (8.0–13.5)
NPY108 (94–121)1172-160 (104–132)105 (97–110)1182-160 (106–127)
SP1.4 (1.2–1.8)  1.7 (1.4–2.1)1.3 (1.1–1.5)  1.4 (1.0–1.7)
CRF42 (38–48) 41 (39–48)42 (39–45) 42 (39–44)
  • Plasma levels of gastrointestinal peptides (pmol/l; median, interquartile range (IQR)).

  • 2-150 p<0.05,

  • 2-160 p<0.01, plasma levels after lipid compared with after saline.

  • CCK, cholecystokinin; PP, pancreatic polypeptide; PYY, peptide YY; VIP, vasoactive intestinal polypeptide; NPY, neuropeptide Y; SP, substance P; CRF, corticotrophin releasing factor.